• Sonoma Pharmaceuticals increased the size of its at-the-market equity program to USD 3.64 million under its sales agreement with Ladenburg Thalmann.
• Supplement filed to raise the aggregate offering amount to USD 3.64 million, including 1,495,830 registered shares not yet sold.
• Sold 173,073 shares for USD 574,633 under the program from Sept. 26, 2025 through June 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-004975), on June 18, 2026, and is solely responsible for the information contained therein.